Literature DB >> 1439539

Effect of Helicobacter pylori on parietal cell sensitivity to pentagastrin in duodenal ulcer subjects.

R S Chittajallu1, C A Howie, K E McColl.   

Abstract

We have investigated the possibility that hypergastrinaemia in chronic Helicobacter pylori infection is a compensatory response to reduced parietal cell sensitivity to gastrin. The acid response to 45-min infusions of pentagastrin at sequential doses (micrograms/kg/h) of 0, 0.031, 0.062, 0.124, and 0.6 was compared before and 1 month after eradication of H. pylori in eight duodenal ulcer patients. The median acid outputs (mmol/h) with the respective infusions were 5.0, 7.5, 26.5, 30.8, and 37.0 when H. pylori-positive and similar at 4.5, 7.1, 22.7, 28, and 31.5 when H. pylori-negative. The median estimated dose of pentagastrin required to produce 50% maximal response (D50) was similar before (0.060 micrograms/kg/h) and after (0.057 micrograms/kg/h) eradication of H. pylori. The median estimated maximal response to pentagastrin (mmol/h) was also similar before (39.2) and after (32.3) treatment. The median basal gastrin concentration was 48 ng/l (range, 22-77) before treatment and fell to 33 ng/l (range, 8-37) after eradication of H. pylori (p = 0.03). These findings show that the parietal cell sensitivity to pentagastrin is unaffected by chronic H. pylori infection in duodenal ulcer subjects and that the hypergastrinaemia cannot be attributed to the bacterium inhibiting parietal cell function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1439539     DOI: 10.3109/00365529209000154

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

2.  Helicobacter pylori eradication, duodenal ulcer healing, and gastric secretory state.

Authors:  J A Louw; I N Marks
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

3.  Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.

Authors:  E el-Omar; I Penman; C A Dorrian; J E Ardill; K E McColl
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

4.  Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of helicobacter pylori in duodenal ulcer patients. A controlled study.

Authors:  F Parente; G Maconi; O Sangaletti; M Minguzzi; L Vago; G Bianchi Porro
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

5.  Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori.

Authors:  S F Moss; J Calam
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

6.  Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17.

Authors:  G Mulholland; J E Ardill; D Fillmore; R S Chittajallu; G M Fullarton; K E McColl
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

7.  Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis.

Authors:  Y Yasunaga; Y Shinomura; S Kanayama; M Yabu; T Nakanishi; Y Miyazaki; Y Murayama; J J Bonilla-Palacios; Y Matsuzawa
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

8.  Gastrin and somatostatin in Helicobacter pylori infected antral mucosa.

Authors:  L Odum; H D Petersen; I B Andersen; B F Hansen; J F Rehfeld
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

9.  Reduced secretion of epidermal growth factor in duodenal ulcer patients with Helicobacter pylori infection.

Authors:  X Q Chen; W D Zhang; B Jiang; Y G Song; R Z Reng; D Y Zhou
Journal:  World J Gastroenterol       Date:  1997-03-15       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.